Cerevel Therapeutics Holdings, Inc. - Common Stock (NQ:CERE)

44.96 UNCHANGED

Last Price Updated: 4:15 PM EDT, Jul 31, 2024 Add to My Watchlist

Price and Volume

Volume	0
Open	44.96
Bid (Size)	44.97 (20)
Ask (Size)	44.98 (146)
Prev. Close	44.96
Today's Range	44.96 - 44.96
52wk Range	N/A - N/A
Shares Outstanding	156,832,992
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

CERE Investors Have the Opportunity to Lead the Cerevel Securities Fraud Lawsuit with Faruqi & Faruqi, LLP

June 03, 2025

From Faruqi & Faruqi, LLP

Via Business Wire

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cerevel Therapeutics

June 02, 2025

From Faruqi & Faruqi LLP

Via GlobeNewswire

Performance

More News

CERE Deadline: Rosen Law Firm Urges Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights

May 23, 2025

From Rosen Law Firm

Via Business Wire

Lowey Dannenberg Notifies Cerevel Therapeutics Holdings, Inc. (“Cerevel” or the “Company”) (NASDAQ: CERE) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $50,000 in Losses to Contact the Firm

May 16, 2025

From Lowey Dannenberg, P.C.

Via GlobeNewswire

Faruqi & Faruqi Reminds Cerevel Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 3, 2025 - CERE

May 11, 2025

From Faruqi & Faruqi LLP

Via GlobeNewswire

May 07, 2025

From Lowey Dannenberg, P.C.

Via GlobeNewswire

April 29, 2025

From Lowey Dannenberg, P.C.

Via GlobeNewswire

INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cerevel Therapeutics

April 26, 2025

From Faruqi & Faruqi LLP

Via GlobeNewswire

ROSEN, A TOP RANKED LAW FIRM, Encourages Cerevel Therapeutics Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CERE

April 25, 2025

From The Rosen Law Firm PA

Via GlobeNewswire

April 25, 2025

From Lowey Dannenberg, P.C.

Via GlobeNewswire

April 21, 2025

From Lowey Dannenberg, P.C.

Via GlobeNewswire

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Cerevel Therapeutics Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CERE

April 18, 2025

From The Rosen Law Firm PA

Via GlobeNewswire

April 18, 2025

From Lowey Dannenberg, P.C.

Via GlobeNewswire

Robbins LLP Reminds CERE Stockholders With Large Losses to Contact the Firm for Information About the Class Action Lawsuit on Behalf of Former Cerevel Therapeutics Holdings, Inc. Shareholders

April 16, 2025

From Robbins LLP

Via GlobeNewswire

April 14, 2025

From Lowey Dannenberg, P.C.

Via GlobeNewswire

CEREVEL ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Cerevel Therapeutics Holdings, Inc. and Encourages Investors to Contact the Firm

April 10, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

Rosen Law Firm Urges Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) Stockholders to Contact the Firm for Information About Their Rights

April 09, 2025

From The Rosen Law Firm, P.A.

Via Business Wire

Cerevel Therapeutics Holdings, Inc. Shareholder Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit on Behalf of Former CERE Shareholders

April 07, 2025

From Robbins LLP

Via GlobeNewswire

Entwistle & Cappucci LLP Files a Securities Class Action Against Cerevel Therapeutics Holdings, Inc., Bain Capital Investors, LLC and Pfizer, Inc.

April 04, 2025

From Entwistle & Cappucci LLP

Via Business Wire

Entwistle & Cappucci LLP is Investigating Potential Federal Securities Law Violations in Connection with Cerevel Therapeutics Holdings, Inc. (CERE)

March 31, 2025

From Entwistle & Cappucci LLP

Via Business Wire

CERE Investors Have Opportunity to Join Cerevel Therapeutics Holdings, Inc. Fraud Investigation with the Schall Law Firm

February 12, 2025

From The Schall Law Firm

Via Business Wire

CERE Investors Have the Opportunity to Join Investigation of Cerevel Therapeutics Holdings, Inc. with the Schall Law Firm

June 18, 2024

From The Schall Law Firm

Via Business Wire

CEREVEL SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation into Fairness of Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) Buyout and Encourages Investors to Contact the Firm

June 11, 2024

From Kaskela Law LLC

Via Business Wire

Calling All Cerevel Therapeutics Holdings, Inc. (CERE) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses

June 05, 2024

From Bronstein, Gewirtz & Grossman, LLC

Via Business Wire

10 Health Care Stocks Whale Activity In Today's Session ↗

June 04, 2024

Via Benzinga

Frequently Asked Questions

Is Cerevel Therapeutics Holdings, Inc. - Common Stock publicly traded?

Yes, Cerevel Therapeutics Holdings, Inc. - Common Stock is publicly traded.

What exchange does Cerevel Therapeutics Holdings, Inc. - Common Stock trade on?

Cerevel Therapeutics Holdings, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Cerevel Therapeutics Holdings, Inc. - Common Stock?

The ticker symbol for Cerevel Therapeutics Holdings, Inc. - Common Stock is CERE on the Nasdaq Stock Market

What is the current price of Cerevel Therapeutics Holdings, Inc. - Common Stock?

The current price of Cerevel Therapeutics Holdings, Inc. - Common Stock is 44.96

When was Cerevel Therapeutics Holdings, Inc. - Common Stock last traded?

The last trade of Cerevel Therapeutics Holdings, Inc. - Common Stock was at 07/31/24 04:15 PM ET

What is the market capitalization of Cerevel Therapeutics Holdings, Inc. - Common Stock?

The market capitalization of Cerevel Therapeutics Holdings, Inc. - Common Stock is 7.05B

How many shares of Cerevel Therapeutics Holdings, Inc. - Common Stock are outstanding?

Cerevel Therapeutics Holdings, Inc. - Common Stock has 7B shares outstanding.